All Updates

All Updates

icon
Filter
Funding
Metagenomi raises USD 100 million in Series B extension
Human Gene Editing
Jan 5, 2023
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
Human Gene Editing

Human Gene Editing

Jan 5, 2023

Metagenomi raises USD 100 million in Series B extension

Funding

  • California-based gene editing biotechnology company Metagenomi has raised an additional USD 100 million in a Series B extension.This round was co-led by Novo Holdings A/S, Catalio Capital Management, and SymBiosis, with participation from new and existing investors, including Leaps by Bayer and Moderna, bringing the total funds raised by the company to USD 457 million. Furthermore, Novo Ventures’ Partner Ray Camahort will join the company’s board of directors as an observer. 

  • The new funds will be used to advance its lead programs through preclinical developments and into clinical proof-of-concept studies. Furthermore, the company plans to expand its targets for preclinical proof-of-concept studies using its proprietary discovery engine.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.